# Large scale single-cell gene rearrangement detection with a microfluidic device

> **NIH NIH R01** · LOMA LINDA UNIVERSITY · 2023 · $1

## Abstract

Acute myeloid leukemia (AML) contributes to 32% of all adult leukemia and
remains one of the most clinically devastating cancers. Currently, AML diagnosis, risk
stratification and treatment selection are mainly based on cytogenetic abnormalities,
which suffers from low sensitivity and low resolution. To overcome this technical hurdle,
we propose to use single-cell RNAseq with microfluidic devices to generate a molecular
version of AML cytogenetic profile including all mRNA abnormalities from a large
number of leukemia cells, a technique we have named S-CytoSeq. This molecular S-
CytoSeq profiling provides fusion genes (FG) and alternative splicing (AS) profiles at
single-cell resolution and will have a significant clinical impact on AML treatment. The
ultimate translational goal is to replace conventional cytogenetics with S-CytoSeq.

## Key facts

- **NIH application ID:** 10694035
- **Project number:** 5R01CA251848-05
- **Recipient organization:** LOMA LINDA UNIVERSITY
- **Principal Investigator:** John Zhong
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1
- **Award type:** 5
- **Project period:** 2020-07-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10694035

## Citation

> US National Institutes of Health, RePORTER application 10694035, Large scale single-cell gene rearrangement detection with a microfluidic device (5R01CA251848-05). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10694035. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*